TK216 — Investigational Agent
Other · Phase 1/2 · Oncternal Therapeutics
Mechanism of Action
Small molecule that binds the EWS-FLI1 fusion oncoprotein and disrupts its protein-protein interactions (notably with RNA helicase A), inhibiting the aberrant transcriptional program that drives Ewing sarcoma.
Investigational Indications
- Relapsed/refractory Ewing sarcoma